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Summary
Drug Information Centers (DIC) have an important place in the health care process 
since they provide independent and updated information. A search was developed 
in Medline, Science Direct, Academic Search Complete, LILACS and Academic 
Google in order to know the state of the art of DIC around the world. Regarding to 
a timeline, the first European DIC was created in 1960 and studies that described 
local situation were identified in 1996 and 2001. Thereafter, in the United States 
the first DIC was created in 1962 and 3 studies that describe DIC characteristics 
and changes trough time were identified between 2003 and 2008. Moreover, DICs 
were created in Singapore in 1980 and in Venezuela in 1981. In India was created 
a DIC in 1997. Subsequently, the WHO performed workshops in 2006 in order 
to create new centers in this country. In Asia was conducted a study in 1996 that 
identified 4 DIC. Concerning Latin America were found studies that describe local 
DIC from Brazil (2001) and Costa Rica (2003). Also, the network of Latin Amer-
ican and Caribbean DICs (REDCIMLAC) was created in 2011. In all consulted 
studies the DICs features were described including type of questions, professionals 
and infrastructure among others. Some of these studies included a comparison with 
the WHO technical document.
Keywords: Drug Information Center, rational drug utilization.
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Resumen
Centros de información de medicamentos. Una visión global del 
concepto
Los Centros de Información de Medicamentos (CIM) ocupan un lugar importante 
en el proceso de atención en salud al proporcionar información independiente 
y actualizada. Con el fin de conocer el estado del arte de los CIMs alrededor del 
mundo, se desarrolló una búsqueda en las bases de datos Medline, Science Direct, 
Academic Search Complete, LILACS y en Google Académico. Revisando cronoló-
gicamente la creación de CIMs, se encontró que el primero fue fundado en Europa 
en 1960. Posteriormente, se crearon en Estados Unidos en 1962, Singapur, 1980 y 
Venezuela, 1981. En India se fundó un CIM en 1997, posteriormente la OMS dictó 
talleres en ese país para fortalecer la creación de nuevos CIMs en 2006. En Asia se 
realizó un estudio en 1996 que identificó cuatro CIMs. En cuanto a Latinoamérica, 
se encontraron estudios de Brasil (2001) y Costa Rica (2003) que describen los 
CIMs locales. Adicionalmente, en 2011, se creó la red de CIMs de Latinoamérica y 
el Caribe (REDCIMLAC). En todos los estudios consultados se identificaron carac-
terísticas de funcionamiento de los CIMs, como infraestructura, tipo de consultas, 
personal, entre otras. Algunos de estos estudios incluyeron una comparación con el 
documento técnico de la OMS.
Palabras clave: Centro de Información de Medicamentos, uso racional de medica-
mentos
Introduction
More than 50 years after the development of the concept of Drug Information Center, 
they occupy an irreplaceable position in the health care process, to be the ideal sources 
of scientific information for the user through the available database, to receive appro-
priate information to solve their problem or special need [1].
The Pan American Health Organization (PAHO) defines Drug Information Cent-
ers (DIC) as operational units that provide technical and scientific information about 
drugs in an objective and timely manner. Also states that they constitute an optimal 
strategy to meet particular needs of information. To do this, the DIC have databases 
and sources of drug information and trained professionals that generate independent 
information relevant to the requests that are made or any need identified [2]. Other 
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authors define a DIC as “an institution dedicated to provide objective, independent 
and current information on drugs and their use, and communicate to the different 
categories of users for better understanding and benefit of patients” [1]. On the other 
hand, PAHO defines Drug Information Services (DIS) as part of the activities of phar-
maceutical services of a health institution with essential presence of the pharmaceutical 
professional who provides drug information services supported by scientific sources, 
updated and independent [1]. Therefore, DIS belongs to an institution and provides 
information services only within it. The overall objective of the DIC is to promote 
rational drug use through technical-scientific, objective, current, timely and relevant 
duly processed and evaluated information [2].
It is generally accepted that the DIC have two basic functions: the development of pas-
sive information addressed to solve or contribute to the solution of problems related to 
drug use in individual cases, and the development of Active Information, represented 
by education activities, dissemination of information and research in the field of  drugs 
[1]. Within a DIC can specify the following functions: attention to drug information 
questions, information dissemination, research and education [1-2].
PAHO has raised some basic requirements to run a DIC, which contemplates a physi-
cal area used exclusively for the DIC and with sufficient capacity for normal operation 
(with an area for the reception of requests for information, for the library and work 
area or to read and assess the information); general office equipment (computer with 
printer and Internet access, microfiche reader, copier and external hotline and fax serv-
ices); information resources including primary sources (journals); secondary (indexes, 
abstracts, databases) and tertiary (books, abstracts, forms), human resource consists of 
a center director (preferably a pharmacist or a doctor) with expertise in information, 
clinical pharmacology and therapeutics.
 Attendees can be internal, students or interns and secretary, and funding sources that 
could be agreements between public and private institutions as long as it is never forgot-
ten the preservation of the independence of the information supplied by the center or 
the collection of services provided by the DIC preferably with differential scales [1- 2].
The first Drug Information Centre in Europe was created in 1960 in the UK. Since 
then they have been developing formal DICs worldwide in order to provide accurate 
and timely information in response to specific questions on drugs [3].
The above guidelines PAHO Drug Information Centers, which were raised in 1995 
and 1997 [1-2] define the fundamental aspects of a DIC operation. However, some of 
these requirements may be obsolete or need an update.
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Methodology
In order to identify whether the concept of DIC varied in different countries or 
whether there were differences in their functioning, a narrative review by mean search 
in Medline, Science Direct and Academic Search Complete, available on the platform 
SINAB (Universidad Nacional de Colombia Library) was performed, as well as in the 
LILACS database. Descriptors were used as search terms “drug information center”, 
“drug information service” and “rational use of medicines drugs utilization”. In the case 
of databases searched through SINAB platform, only articles with full text available 
were included.
Additionally a search in Google Academic and the Virtual Health Library, NLM were 
performed in order to complement the information on the state of the art of DIC in 
Latin America.
Results and discussion
The search strategy found 445 articles. After removing duplicate papers and those 
papers that do not contain the term “Drug Information Center” in the title, it was 
proceeded to review the abstracts to identify those papers related to definition and 
functioning of DIC. Finally, 11 papers were available for review. Figure 1 shows the 
flow diagram. 
Total papers in search =445
Available for pre-selection 
N=439
Pre selection by Title N=51






Figure 1. Flow diagram of articles included in the review.
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This search allowed finding previous overviews about DIC. However, the scope of the 
found papers was national or about a specific region. This review sought to provide a 
description worldwide of DIC.
The first European DIC was created in United Kingdom in 1960. Since then, it had 
been developing formal DIC around the world [3]. 
In 1996 Müllerová and Vlcek implemented a survey of activities of 129 drug informa-
tion centers in 18 European countries. The response rate was 71.3% (n=92) and the 
information from 84 DICs that met the inclusion criteria was analyzed. The results 
of the study show that DICs are affiliated mainly with European hospitals (68%), and 
rarely to pharmacy (6%) or medical schools (8.3%).
The activities of the DICs included service response questions (98%), publishing 
newsletters (68%), participation in committees of Pharmacy and Therapeutics (F & T) 
(63%), tutorials (61%) and use evaluation drug (52%). The most frequently employees 
of DICs are the pharmacists, usually 1 or 2 full time or part time. By analyzing the 
query resolution service it was found that 56% of the DICs offer their services only 
to health professionals and 43% to both these professionals and the general public. 
The questions were mainly related to adverse effects, indication / therapeutic use and 
dosage of drugs. Most DICs (91%) frequently recorded their activities in a compu-
ter database. Quality assurance activities were developed in 75% of centers, usually by 
means of reviews (58%) or feedback questionnaires (32%). The most frequently used 
information sources were Martindale-The Extrapharmacopeia, journals such as Lancet 
and databases such as Medline and Micromedex. The DICs are generally funded by 
the organizations they are affiliated with. The 9.5% of DICs charged fees for special 
activities [4].
In 2001 Scala et al. published a study of Italian Information Centers. The results resem-
bled European and American trends [3]. It was found that the number of DICs in Italy 
grew rapidly since 1985, but then stalled in the 90s. According to the authors, this 
behavior is due to the availability of computerized drug information designed to be 
user friendly, many of them online, which could facilitate to satisfy the users informa-
tion needs without consulting a formal DIC. Comparing the results with those found 
in a survey conducted in Italy in 1997, a greater number of DICs acquired direct Inter-
net access (60%), allowing pharmacists to use online resources. Another finding was an 
increase in the number of DICs produced newspapers and newsletters (48% in 1997 
vs. 90% in 1999), reflecting the increased interest in active information [3]. 
In the United States the first Drug Information Center was created in 1962 at the Univer-
sity of Kentucky and since then some studies have been published which review various 
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aspects of U.S. DICs. Rosenberg et al. have studied the national scene DICs using sur-
veys since 1974, in 2003 it was conducted a study that aimed to make a diagnosis of 
the current state of the centers and compare the results with those of similar surveys 
applied in the past 30 years. 151 DICs were contacted, and 119 of them responded to 
the survey (79%); 81 met the inclusion criteria. 
The U.S. centers were located in 33 states, the District of Columbia and Puerto Rico. 
The results showed that most DICs are affiliated with hospitals or medical centers 
(72%) and pharmacy schools (61%). The staff was composed mainly of pharmacists, 
students, interns, residents, secretaries and administrative staff. Only 12% of the DICs 
reported not having at least one full-time pharmacist, 71% of pharmacists were doc-
tors of pharmacy (PharmD) and 24% had bachelor’s degree, plus 9% had a master’s 
degree in science, master’s degree in business administration, master of public health, 
or doctoral (Ph.D.), 94% of reported DICs had within its staff at least 1 pharmacist 
PharmD title. 
The services offered by DICs, from the U.S, in addition to answering questions about 
medications, included the preparation of newsletters (80%), participation in activi-
ties of the pharmacy and therapeutics committees (79%), training or education (79%), 
development of administrative tasks not directly related to the DIC (66%), literature 
search queries not related to daily living (65%), reporting of adverse reactions (65%), 
and development of medicines use reviews (63%). The main consultants were phar-
macists (40.6%), doctors (24.4%) and nurses (15%). The questions were related more 
often with therapeutic issues (17%), adverse reactions (16.2%), identification of U.S. or 
foreign products (14.3%) and dosage (10.1%). For the system used to access, store and 
retrieve the questions and answers, 38% of the DICs used a computerized database, 
32% use a paper system and 30% used both. A formal program of quality assurance 
had been implemented in 51% of the DICs and in 18% it was being developed, the 
consultation service drug information is most commonly evaluated using criteria such 
as accuracy, that the answer is complete, documentation references used, timeliness, 
clarity, objectivity and impact on patient care. 
In the U.S. centers, the most common method for judging was an internal review by 
a person (70%), followed by feedback from the applicant (36%), and internal review 
by a committee (21%). The most commonly reported source acknowledged as use-
ful was Micromedex Healthcare Series, followed by Medline and AHFS Drug Infor-
mation. The DICs funding came primarily from U.S. hospitals and medical centers 
(73%) and schools and universities (37%), other sources including charging fees for 
certain activities (19%), federal and state aid (5%), pharmaceutical companies (4%) 
and non-governmental organizations and foundations (1%). When comparing these 
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results of 2003 with those of similar surveys applied in the past 30 years, it was found 
that the number of DICs decreased in the last decade and the number of pharmacists 
and other staff was the lowest in the last 30 years. Pharmacists were better trained then 
than in the past and a large percentage had high educational qualifications. The serv-
ices remained consistent with previous findings, except for the increased participation 
in training and education of pharmacy students and residents. The percentage of DICs 
system with formal quality assurance did not change significantly in the past decade 
and funding resources and service fees remained the same [5].
In 2008, Rosenberg et al. conducted a study that surveyed 89 U.S. DICs previously 
identified in 2003 to determine if they still existed and if they had experienced changes. 
We found that 75 (84%) of the 89 DICs remained active. The most notable change 
in the activities was the increase in the time spent on education to students in the 
area of health (53%), in supporting the pharmacovigilance program of the institution 
(44%), and to provide system support information (36%). No changes in the number 
of employees were observed. With respect to the number of questions received, 29% 
of the DICs reported an increase, 42% a decrease and 29% no change, 70% reported 
having had an increase in the number of complex questions, while 53% reported an 
increase the time required to answer each question [6].
In the United States, FDA sponsored two DICs, one located in the (Center for Bio-
logics Evaluation and Research [CBER]) and another in the Center for Drug Evalua-
tion and Research (CDER). Each DIC provided product information and regulatory 
guidance. Representing the regulatory agency, these DICs provided services to a wider 
range of applicants than those DICs belonging to hospitals, universities and the phar-
maceutical industry. In essence, served as a liaison between the public and FDA [7].
The CBER had divided his work into two branches DIC: the first was in charge of 
consumer-related issues and the second to assist manufacturers and technical training, 
the first was the one who answered questions on issues related to eligibility criteria for 
blood and tissues donor, approval of products, and tips for finding clinical trials in a 
specific search. The human resource CBER DIC is comprised of individuals who had 
received a course of at least 30 hours of education in science, public affairs specialists 
and education. Each branch had about 6 people with a wide range of professions, such 
as nursing, social work, animal science, journalism and molecular genetics. About 600 
questions were answered per month and the response time of most queries was approx-
imately 1 to 3 days. On the CDER, Division of Drug Information (DDI) was responsi-
ble for answering questions from the public about products for human use. The topics 
of the queries were related to clinical aspects of particular molecule or a group of drugs 
and drug regulation either new, as generic or OTC. In the DDI 12 pharmacists and 
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one nurse worked and they received about 1,000 phone calls and 900 emails per week. 
The answers were usually given by phone the next day and the mails were responded 
within two days [7]. The main difference of these DICs of the FDA with those DICs 
of hospitals and universities was that the former does not provide medical advice to 
abstain from prescribing information approved by the FDA; therefore, these DICs did 
not necessarily perform an extensive literature search that took into account other uses 
other than those approved by the FDA. The DDI had great confidence in the informa-
tion posted on the FDA Web site but also used traditional information resources of 
a DIC. An additional reference used was the internal databases that allow to review 
previously resolved questions. The two DICs answered questions that might require 
the use of multiple sources in their respective divisions, including offices of pro- duct 
review, quality, medical policies, etc. [7].
Reviewing the situation in other parts of the world, a study was found in 2006 in 
Bangalore, India, where the World Health Organization (WHO) conducted a train-
ing workshop which included an introduction to information activities of drugs and 
rational use thereof. The course was part of a program to spread the influence of drug 
information centers and training programs in clinical pharmacy that had been devel-
oped in southern India during the previous 10 years. This program was coordinated 
by the Board of Pharmacy of the state of Karnataka (KSPC) and sponsored by the 
WHO office in India [8]. The KSPC founded a DIC in 1997 but the project included 
the creation of five independent DICs across the country [9]. The projected centers 
might provide information to health personnel and the general public, and also meet 
the reporting of suspected adverse reactions [8]. These centers would act as state DICs 
able to respond to the level of detail requested [9]. The WHO planned to grant lim-
ited financial resources to purchase information resources but in the long term would 
require financial support from the state [8]. As part of the financing it would receive 
an initial amount to purchase reference books and extra money monthly for 6 months 
for recurrent expenditure [9].
Very little was known about the DICs of eastern Asia. In 1996 a drug information 
pharmacist handed a formal setting and it was a relatively new concept in this part of 
the world. It was not until 1980 that the first organized DIC was created in Singapore. 
Then in 1996, Lim and Chui conducted a study conducted by pharmaceutical DICs 
there. At the time of the study there were 3 DICs located in hospitals and 1 in the Phar-
maceutical Department of the Ministry of Health. Hospitals were in charge for the 
funding for the first 3, while the latter were funded by the government and no fees were 
charged in cases for services or external applicants. All centers were well equipped with 
cabinets, telephone, fax, photocopier, computers, and Internet access (with the excep-
tion of one DIC). The most used bibliographic resource was Micromedex, followed 
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by Martindale, AHFS Drug and compendia as Index of Malaysia & Singapore and Brit-
ish National Formulary. Less than 4% of the consultations needed secondary sources 
of literature, but Medline was the resource of choice in such cases. All DICs had access 
to a medical library.
Of the four DICs of Singapore surveyed, three had one on staff full-time pharmacist. 
None had any formal training in drug information as graduate training; one of them 
had a master’s degree in Clinical Pharmacy, while another was studying for the same 
title. There were no quality assurance programs except for a center that was sending 
feedback forms to users once a year, but all DICs had developed operational policies 
and procedures manuals. 
The four centers of Singapore recorded manually each question received; these records 
contained the date, the applicant’s name, a contact number, the question asked, the 
answer given, the response time, references used and the signature of the pharmacist 
who gave the information. The average monthly consultation was between 92 and 259. 
Most queries were answered in five minutes, only less than 10% required more than 
1 hour to be resolved. In approximately 80% of the consultations was used only one 
reference. The most frequent consultants were physicians (51%), pharmacists (32%) 
and nurses (10%). 
In hospital’s DICs, the most common questions were dosing, availability of a drug and 
identification; others were choosing a therapy, administration, adverse effects and drug 
safety. In the DIC located in the Ministry of Health request printed literature con-
sultation drug was the most common, followed by questions about adverse reactions, 
product availability, formulation and identification [10].
Latin American Situation
In 2003, Costa Rica performed a study diagnosis of DICs belonging to national public 
institutions, in order to determine the degree of fit to the requirements of the PAHO. 
The results showed that there were 7 public units drug information: 4 DICs and 3 
Drug Information Services (DIS), of which 6 were located in a hospital and one at a 
university. The primary sources of information suggested by PAHO were not avail-
able in 5 of the centers. Of the 36 recommended tertiary sources, 15 were not avail-
able at any of the centers. The most frequent activities were resolving queries of the 
community hospital or outpatient users, implementation of education programs for 
patients and risk groups and programs for student training rotation. The authors con-
clude that the activities of different DIC in Costa Rica were similar to each other, not 
just respond to the guidelines of the PAHO, but have similarities with the activities 
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and operations of other DIC worldwide, also showed that the bibliographical support 
must be strengthened [11].
Moreover, Brazil had established a nationwide network of DIC, which was organized 
on a decentralized, non-hierarchical manner and operates on cooperation protocols. 
The network was called The Brazilian Drug Information System (SISMED) and was 
the result of inter-agency effort to support multidisciplinary health team, optimizing 
the resources available in this area and promoting rational drug use. Also it could sup-
port the development of the pharmaco-epidemiological studies in the country, with 
emphasis on pharmacovigilance as one of the activities the DIC could do. Among the 
strategies to implement SISMED were specialized professionals and frequent meetings 
of the coordinators of the DICs to share experiences. Training courses had been given, 
and national meetings of professional from the DICs had been made, activities that 
have helped the development of the national network and the strengthening Brazilian 
DIC of drug information system in Brazil [12].
In 1992 the Federal Council of Pharmacy of Brazil (CFF), together with the Pan 
American Health Organization, created the Brazilian Center for Drug Information 
(CEBRIM-Centro Brasileiro de Informação sobre Medicamentos). Silva et al.  con-
ducted a cross-sectional descriptive study between November 2000 and October 2001 
in order to analyze the results of CEBRIM and the opinion of its users [13]. 
The results were that CEBRIM answered 970 questions in the study period, with a 
monthly average of 81 questions, showing that this DIC answered more questions 
than many others Brazilian DICs at a rate of 30%. The percentage of patients who con-
sulted the center was very low (34.5%). In 44% of cases the answer was delivered in 24 
hours. Of the users surveyed, 89.5% reported receiving response time, 88% thought it 
was clear, objective and 85% that the information was complete. The 99.2% of patients 
declared its intention to use the DIC service. The authors conclude that the CEBRIM 
served its purpose of providing drug information in an objective, timely and updated 
manner. It could be considered that the center plays an important role in promoting 
rational drug use and is a useful tool for health professionals in the care of patients [13].
Since 2011 the Latin America and the Caribbean DIC Network (REDCIMLAC 
for its acronym in Spanish) has been formed, as an initiative of the Drug Utilization 
Research Group-LA and with support from PAHO/WHO to link the DIC in Latin 
America and the Caribbean, respecting their autonomy (web page: http://web2.red-
cimlac.org/) [14]. This network consists of 19 countries and 29 information centers. 
These centers were created and in some cases supported by PAHO / WHO so they all 
retain the basic guidelines of this organization white paper [14].
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In figure 2 the creation of the DICs included in this review is summarized by year.
1960 1962 1980 1981
1992 1997 2011
• 1st DIC in
    United
    Kingdom
• 1st DIC in
    the USA  
• 1st DIC in
    Singapore
• 1st DIC in
    Venezuela
• Brazilian
   Center for
   Drug
   information
   was created
• 1st DIC in
    India
• REDCIMLAC
   was created
Figure 2. DIC creation timeline. 
Although it was not possible to compare the same variables for all DIC it could be 
observed that they did not limit solely to answer consultations but they also participate 
in different activities, in some cases in education-related activities, in other cases in the 
productions of bulletins, participation in pharmacy and therapeutics committees, and 
other activities. It was also observed that most belong to hospitals or pharmacy schools. 
With respect to financing, it was found that the economic resources come from inde-
pendent sources like hospitals, government, universities, and the charging of fees for 
consultation; only one DIC study in the US reported that 4% of DIC receives eco-
nomic resources from the pharmaceutical industry.
It is concluded that the concept and functions of the DIC are constant over time and 
across countries. As expected, an increase in the number of countries with an estab-
lished CIM is evident worldwide.
254
Mónica Alexandra Nova Manosalva, José Julián López Gutiérrez, Martin Cañas
Acknowledgements
The authors thank the Universidad Nacional de Colombia and the Network of Latin 
America and Caribbean Drug Information Centers (REDCIMLAC).
Disclosure statement
No potential conflict of interest was reported by the authors.
References
1. R. D’Alessio, U. Busto, N. Girón, “Guía para el desarrollo de servicios farmacéu-
ticos hospitalarios: información de medicamentos”, Serie Medicamentos Esen-
ciales y Tecnología N. ° 54. Organización Panamericana de la Salud, 1997.
2. Grupo de trabajo regional sobre centros de información de medicamentos de la 
Organización Panamericana de la Salud, “Centros de Información de Medica-
mentos: una estrategia de apoyo al uso racional de medicamentos”, PAHO HQ 
Library, Santo Domingo, 1995.
3. D. Scala, A. Bracco, S. Cozzolino, A. Cristinziano, C. De Marino, A. Di Mar-
tino, E. Gonzalez, A. Mancini, F. Romagnuolo, L. Zeuli, Italian drug informa-
tion centres: benchmark report, Pharm. World Sci., 23, 217 (2001). 
4. H. Müllerová, J. Vlcek, European drug information centres-survey of activities, 
Pharm. World Sci., 20, 131 (1998).
5. J.M. Rosenberg, T. Koumis, J.P. Nathan, L.A. Cicero, H. McGuire, Current sta-
tus of pharmacist-operated drug information centers in the United States, Am. J. 
Health-Syst. Pharm., 61, 2023 (2004).
6. J.M. Rosenberg, S. Schilit, J.P. Nathan, T. Zerilli, H. McGuire, Update on the 
status of 89 drug information centers in the United States, Am. J. Health-Syst. 
Pharm., 66, 1718 (2009).
7. K.C. Dada, M.E. Kremzner, S.K. Bhanot, R. Lal, Role of FDA’s drug informa-
tion centers, Am. J. Health-Syst. Pharm., 65, 803 (2008).
8. International Pharmaceutical Federation (FIP), Developing drug information 
centres in India, WHO Drug Information, 21, 130 (2007). 
Drug information centers: An overview to the concept
255
9. BioBoard, KSPC to Set up Drug Information Centers with WHO Funding, 
Asia Pacific Biotech News, 11, 1 (2007).
10. L.Y. Lim, W.K. Chui, Pharmacist-operated drug information centres in Singa-
pore, J. Clin. Pharm. Ther., 24, 33 (1999). 
11. V. Hall, C. Gómez, F. Fernandez-Llimos, Situation of drug information centers 
and services in Costa Rica, Pharm. Pract. (Granada), 4, 83 (2006).
12. C. Vidotti, R. Hoefler, E.V. Silva, G. Bergsten-Mendes, Sistema Brasileiro de Infor-
mação sobre Medicamentos (SISMED), Cad. Saude Publica, 16, 1121 (2000).
13. E. Silva, L. Castro, L. Bevilaqua, C. Vidotti, R. Hoefler, CEBRIM: the Brazilian 
Drug Information Center: characterization of services provided and user’s opin-
ions, Rev. O.F.I.L., 13, 55 (2003).
14. Red de Centros de Información de Medicamentos de Latinoaméricana y el Car-
ibe. URL: http://web2.redcimlac.org/, consultado en abril de 2013.
How to cite this article
M.A. Nova-Manosalva, J.J. López-Gutiérrez, M. Cañas, Drug information centers: An 
overview to the concept, Rev. Colomb. Cienc. Quím. Farm., 45(2), 243-255 (2016).
